Tempest Therapeutics (TPST) Financials

$1.03

$-0.02 (-1.90%)

As on 04-Sep-2026 17:36EDT

Market cap

$17 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

22.9

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	22.31	--	0.39	0.38	1.81	1.27
Gross Profit	-22.31	--	-0.39	-0.38	-1.81	-1.27
Operating Expenses	18.46	26.58	41.64	29.16	34.64	26.99
Operating Profit (EBIT)	-40.64	-26.58	-42.03	-29.16	-34.64	-26.99
Other Income	--	--	--	--	--	--
Profit before Tax	-40.47	-26.26	-41.84	-29.49	-35.71	-28.30
Provision for Tax	--	--	-41.84	--	1.07	1.25
Profit after Tax (Net Income)	-40.47	-26.26	-41.84	-29.49	-35.71	-28.30
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	--	-28.30

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	-1.09	6.67	19.13	26.77	18.11	36.12
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	6.27	6.95	8.14	15.42	20.70	17.10
Current Liabilities	4.45	3.31	14.22	9.41	7.28	20.03
Total Liabilities	14.08	16.93	41.49	51.60	46.09	73.24

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	7.94	8.66	10.01	11.24	13.14	4.28
Current Assets	1.70	8.27	31.47	40.36	32.95	68.96
Total Assets	11.33	16.93	41.49	51.60	46.09	73.24
Total Debt*	7.56	8.14	15.37	20.66	22.11	18.54
Net Current Assets	--	4.96	17.25	30.95	25.67	48.94

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-26.82	-33.03	-27.36	-31.07	-25.96
Cash Flow from Investing Activities	--	--	-0.44	-0.17	-0.56	-0.10
Cash from Financing Activities	--	4.26	24.50	35.60	11.40	59.06
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-4.64	-6.33	-1.50	-1.37	-3.39	-4.21
Cash EPS ($)	--	-6.26	-1.49	-1.35	-3.33	-4.16
Adjusted Book Value ($)	--	1.61	0.69	1.24	1.72	5.38
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-6.46	-1.18	-1.27	-2.95	-3.86
Free Cash Flow per Share ($)	--	-6.46	-1.20	-1.28	-3.01	-3.88

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-106.54	-102.16	-67.29	-75.27	483.79
ROE (%)	--	-203.63	-182.35	-131.42	-131.70	173.23
ROA (%)	-188.44	-89.91	-89.90	-60.38	-59.85	-58.90
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	16.75	35.71	-44.52	17.74	-26.17	-40.67
Net Profit Growth (%)	6.10	37.24	-41.88	17.41	-26.17	-48.04
EPS Growth (%)	24.38	-3.22	-0.09	0.60	0.19	0.80
Book Value Growth (%)	-102.78	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-0.45	-0.56	-3.21	-0.34	-1.25
Price / Book Value	22.94	1.79	1.22	3.54	0.67	0.98
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.31	-0.48	-0.21	-2.75	-0.09	-0.08
Close Price ($)	1.11	2.87	10.85	57.20	14.95	68.64
High Price ($)	12.23	13.65	78.00	127.01	72.67	540.15
Low Price ($)	1.02	2.80	9.08	2.21	13.78	65.27
Market Cap ($ Cr)	17.04	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	1.22	0.80	0.77	1.22	0.51
Short term debt to equity ratio	-1.18	0.18	0.38	0.20	0.08	0.04
Current Ratio	0.38	2.50	2.21	4.29	4.53	3.44
Quick Ratio	0.38	--	--	--	--	3.36
Interest Coverage	-206.55	-125.87	-30.80	-19.35	-21.07	-21.08

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	318.34	325.99
Payable days	--	--	1,546.91	936.13	211.32	296.51
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.